enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-117.30M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.09 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -55.49% |
| Return on Assets (Trailing 12 Months) | -46.02% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.30 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.30 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.09 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.60 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.73 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.29 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.29 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 66.99M |
| Free Float | 60.02M |
| Market Capitalization | $711.38M |
| Average Volume (Last 20 Days) | 0.36M |
| Beta (Past 60 Months) | -0.29 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 64.16% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |